Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Atsena Therapeutics is raising $55,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Patrick Ritschel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Atsena Therapeutics

ATSENA THERAPEUTICS is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. We have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. The company has an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Its pipeline of clinical and preclinical assets is powered by adeno-associated virus (AAV) technology tailored to overcome the hurdles presented by inherited retinal disease, and its approach is guided by the specific needs of each patient condition. Founded by pioneers in ocular gene therapy, Atsena has a licensing, research, and manufacturing collaboration with the University of Florida and is headquartered in North Carolina’s Research Triangle, an environment rich in gene therapy expertise.

To learn more about Atsena Therapeutics, visit http://atsenatx.com/

Contact:
Patrick Ritschel, Chief Executive Officer
302-290-5544
https://www.linkedin.com/in/patrick-ritschel-aa949160/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved